Blood Disorders Grants

CSL Behring Professor Heimburger Award
Global Research Grant – Coagulation

CSL Behring is committed to supporting long-range progress in the area of coagulation. Based on recent publications and feedback from the medical community, it is important to encourage the next generation of coagulation specialists to medically and scientifically establish themselves, in order to have continued progress in this therapeutic area. CSL Behring will fund the second cycle of a global grant program to support the above objective.

Prof. Dr. Norbert Heimburger, a CSL Behring employee for over three decades, devoted his work to blood coagulation. During that time, he characterized and purified a large number of plasma proteins and was instrumental in making these available to the medical community as therapeutic options. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization.
Due to his determination and constant interaction with leading hemophilia and coagulation specialists, Behring launched the first effectively virus-inactivated FVIII concentrate in 1981. Prof. Dr. Heimburger, honored with the Order of Merit of the Federal Republic of Germany in 1991, retired in 1991 but was still very much involved with CSL Behring as a Scientific Advisor until he passed away in September 2006.

CSL Behring named this grant “CSL Behring - Professor Heimburger Award” to honor Professor Dr. Heimburger.

Funds Available
CSL Behring will offer five (5) global start-up grants of € 20.000 each for the 2009 cycle. No matching funding is a prerequisite for this grant. The grants will be available for preclinical and/or clinical research in the area of coagulation. All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation.

At the end of the year, the recipient will have the opportunity to present the results at CSL Behring, Marburg, Germany.

Eligibility
The grants are targeted at investigators relatively new to the field of coagulation, who hold an MD and who wish to establish their own independent research project in the field of coagulation. It is expected that the person indicated as the investigator for this grant application is the individual who is personally and actively responsible to conduct the research.

Application Procedures
Apply in one of these ways:

Complete the online application form, save it, and e-mail it to heimburger.award@cslbehring.com

Download an application form and send it via the postal service to the address below.

Request one or more hard copies of the application form by mail from the address below, and return the completed form(s) by the postal service to that address.

CSL Behring
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY

Applications consisting of application form, current CV and one-page research proposal must be received by CSL Behring no later than 17 October, 2008 to be considered for the next cycle. Applications should be submitted to the address above. Please note that applications can also be submitted online.

All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation:

Erik Berntorp, MD, PhD
Centre for Thrombosis and Haemostasis
Malmö University Hospital, Malmö, Sweden

Jorge Di Paola, MD
Department of Pediatrics
University of Iowa Hospitals and Clinics, Iowa City, USA

David Lillicrap, MD
Department of Pathology and Molecular Medicine
Queen's University, Kingston, Canada

Johannes Oldenburg, MD
Institute of Experimental Haematology and Transfusion Medicine
University Clinic Bonn, Bonn, Germany

The selection committee will review applications based solely on scientific merit. Applications will initially be screened and the 10 applicants deemed to have the highest chance of success will be asked to submit a more detailed (3-4 page) description of their research project.

Based on their evaluation of the detailed submission, the selection committee will inform CSL Behring of their decision by 15 February, 2009. CSL Behring will then notify the recipients. Grants will be personally awarded by CSL Behring in March 2009.

Inquiries
For questions regarding applications, policy and procedures information, contact:

CSL Behring GmbH
Att. Dieter Pluennecke
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY
T: +49 6421 394191
F: +49 6421 394146

e-mail: heimburger.award@cslbehring.com

3-Year (2009-12)
Follicular Lymphoma Research Initiative Grant
Guidelines and General Instructions for Application
KEY DATES:
Application Release Date: June 1, 2008
Letter-of-Intent Receipt Date: August 1, 2008
Application Receipt Date: September 10, 2008
Peer Review Dates: September 19 – Oct 17, 2008
Applicant Notification Date: March 2009
Earliest Project Start Date: July 1, 2009
SUMMARY:
The Lymphoma Research Foundation (LRF) seeks
innovative proposals for its LRF Follicular
Lymphoma Initiative. The goal of this LRF initiative
is to develop novel therapeutic strategies for the
treatment of follicular lymphoma (FL). To
accomplish this, the LRF seeks proposals that
advance the understanding of the human biology of
follicular lymphoma or that verify molecular targets
for follicular lymphoma therapeutics. The LRF also
believes that coordination of efforts in the
development of therapeutics is needed to accelerate
the pace of research in follicular lymphoma.
RESEARCH OBJECTIVES:
Proposals are welcome in all areas related to follicular lymphoma including etiology,
prevention, pathogenesis, novel therapeutics, translational research including genomics,
proteomics, or biomarkers, clinical trials and outcomes studies. However, the LRF is
particularly interested in receiving proposals in the following areas in follicular
lymphoma:
1. Advancing the understanding of the human biology of follicular lymphoma;
o Understanding of how drug and antibody resistance develops in follicular
lymphoma
o Understanding why aggressive transformation occurs
o Developing ways to prevent aggressive transformation
2. Verifying molecular targets in pre-clinical models for follicular lymphoma
therapeutics;
o Develop assays to measure human FL tumors
o Develop preclinical models that mimic human FL
o Identify or validate molecular targets in human FL tumors or preclinical
models
o Targets to characterize in FL may include, but are not limited to, kinases and
signal transduction pathways, novel cellular targets for development of
monoclonal antibodies, developmental and differentiation pathways, protein
degradation pathways and the proteasome, or transcriptional regulation
ELIGIBILITY:
All principal investigators holding an academic faculty appointment, at non-profit
organizations, or public or private institutions such as universities, colleges, hospitals,
and laboratories, may apply for funding through the LRF Follicular Lymphoma
Initiative. For-profit entities are not eligible to apply for LRF funds, however, should
one of these types of institutions have a relevant therapeutic or research project, they
should contact LRF management to discuss possible public-private partnerships.
APPLICATION PROCESS:
LRF requires prospective applicants to submit a letter of intent (LOI) in order to be
eligible to submit a full proposal. Proposals submitted without a LOI will not be
reviewed. The LOI should include the following:
• Cover letter including name, address, and telephone number of the PI, other key
personnel, and participating institutions;
• Abstract of proposed project, including descriptive title (please do not exceed 350
words);
• Applicant's biosketch.
LRF will perform a preliminary review of these materials to confirm eligibility and the
appropriateness of the proposed research project.
All interested applicants must submit their LOIs online through proposalCENTRAL
(https://proposalcentral.altum.com ) by August 1, 2008.
The full LRF application will be available in early August only for those individuals who
successfully submit a letter of intent by the deadline and are confirmed to be eligible.
MECHANISM OF SUPPORT:
Applications may not exceed $250,000 per year total costs, including indirect costs.
Proposals may be for up to 3-years in duration. The LRF intends to fund 2 applications
for this special research initiative.

3-year (2009-12)
Clinical Investigator Career Development Grant

PURPOSE OF AWARD
The purpose of the Lymphoma Research Foundation’s
(LRF’s) 3-year Clinical Investigator Career Development
Grant is to fund training of clinicians who will
participate in developing new therapeutics and
diagnostic tools for lymphoma. Clinicians with up to
5 years of experience after their first full time faculty
appointment post fellowship are eligible.
The focus of the training is to prepare clinicians to
design and administer clinical studies in lymphoma
and to take on the primary responsibilities for
clinical trial design, protocol writing, Institutional
Review Board (IRB) submission, and publication.
The proposed research plan should develop the
necessary knowledge and clinical research skills
relevant to the investigator’s career goals. The
Grant is designed to provide clinicians with support
to spend a minimum of 35% and up to 50% of their
time implementing clinical studies in lymphoma. A
Career Development Plan is required as part of the
Grant Application.
ELIGIBILITY
1) Applicants must be licensed physicians at a clinical research institution in the U.S. or
Canada for the duration of the LRF Clinical Investigator Grant.
2) Applicants for this award should be clinical physicians including recognized ACGME
accredited specialties (e.g., hematology/oncology, pathology, dermatology, radiation
oncology).
3) As noted above, clinicians with up to 5 years of experience after their first full time
faculty appointment post fellowship are eligible. They should have participated in
developing new therapeutics and/or diagnostic tools for lymphoma.
4) Applicants must demonstrate that they already possess a broad knowledge of
lymphoma biology and treatment and their desire to apply this knowledge to
developing and evaluating new treatments.
5) There must be a Primary Mentor at the applicant’s institution who will oversee the
applicant’s research training. The Primary Mentor may support only one applicant.
6) In addition to the Primary Mentor, the applicant is encouraged to enlist Associate
Mentor(s) to provide specialized training and assistance. The support of an Associate
Mentor with expertise in biostatistics is particularly important.
7) The Clinical Investigator must spend a minimum of 35 to 50 percent of his/her time
in research. This time should be free of major patient care, teaching, or administrative
responsibilities.
8) The Clinical Investigator will have primary responsibility for the design, protocol
writing, IRB submission, conduct, analysis and publication of one or more clinical
trials during the award period.
9) The Clinical Investigator may not hold another competitively applied for fellowship
or career development award during the period of the LRF Grant.
10) Supply and material costs for the clinical research project should be supported by
another grant or from institutional funds. Applicants must provide evidence of
adequate research support.
11) All LRF applications are self-initiated. LRF does not invite applications from selected
individuals, institutions, or laboratories.

Submission Deadline: 5:00PM, September 10, 2008.

All interested grant applicants must submit their applications online through
proposalCENTRAL (https://proposalcentral.altum.com ). Questions
concerning use of the proposalCENTRAL electronic submission system
should be directed to the proposalCENTRAL helpline, which is available for
questions from applicants during normal business hours (8:30 a.m. – 5:00
p.m.), Monday-Friday, EST. Phone: 1-800-875-2562 (toll free) or 703-964-
5840 E-mail: pcsupport@altum.com

2-Year (2009-11)
POST-DOCTORAL FELLOWSHIPS

PURPOSE OF FELLOWSHIP
Research may be laboratory or clinic based, but the
results and conclusions must be clearly relevant to the
treatment, diagnosis or prevention of Hodgkin and/or
non-Hodgkinlymphoma. Areas of research may
include, but are not limited to, etiology, immunology,
genetics, therapies, and transplantation.
ELIGIBILITY
1. Applicants must have completed two years of
their fellowship, or not more than two years as a
junior faculty instructor or assistant professor at
the start of the award period and hold an M.D.,
Ph.D., or equivalent degree.
2. Applicants must be affiliated with a sponsoring
institution in the U.S. or Canada for the duration
of the LRF Grant. Citizenship is not required.
3. Applicant must secure a Sponsor who will
supervise the proposed research project. The
Sponsor’s role is to assure (on behalf of the
Institution) that the specific aims of the project
are met and to present the Institution’s role in the development of the Applicant’s
career. The Sponsor may support only one applicant.
4. Applications are encouraged from qualified individuals without regard to age,
race, religion, sex, creed, national origin, or any other characteristics protected by
law.
5. All LRF applications are self-initiated. LRF does not invite applications from
selected individuals or laboratories.
6. The Fellow must spend a minimum of 80 percent of his/her time in research
without major patient care, teaching, or administrative responsibilities except as
such responsibilities relate directly to a pre-clinical or clinical lymphoma research
project.
7. The LRF Fellow may not hold another competitively applied for fellowship title
during the period of the LRF Grant. However, LRF Grants may be supplemented
by funds from other sources. LRF must be informed as to the sources and the
amounts of all other funding received by the LRF Fellow during the term of the
LRF Grant. Failure to comply may result in termination of the LRF Grant.
8. There is no restriction on the number of times an individual may apply for a LRF
Grant.
9. A previous LRF Fellow shall not be granted support other than in exceptional
circumstances, which is decided on a case-by-case basis.
EVALUATIVE FACTORS
Applications will be reviewed by members of LRF’s Scientific Advisory Board (SAB).
Evaluation of Applications will be based on, but not be limited to the following factors:
• Overall Research Proposal and it’s Relevance and Significance to Lymphoma
• Applicant’s Prior Research Experience
• Applicant’s Potential for Research Career in Lymphoma
• Recommendations
• Assessment of Program and Facilities Available
STIPEND
The LRF Fellowship provides salary support only in the amount of $45,000 for the first
year and $50,000 for the second year. Additionally, $5,000 per year is allotted for the
research project. The Grant does not provide for institutional overhead.
HOW TO APPLY -- PROCESS AND DEADLINES

Lymphoma Research Foundation will be using an electronic grants submission process.
All interested grant applicants must submit their applications online through
proposalCENTRAL (https://proposalcentral.altum.com).

INTERNATIONAL MYELOMA FOUNDATION
2009 BRIAN D. NOVIS RESEARCH AWARD Senior Grant
Provided by donations from private individuals

The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma. This year’s awards will be in the amount of $80,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward prevention and a cure.

QUALIFICATIONS
These awards are targeted to established investigators with a track record in myeloma or related research, and are designed for projects which represent a different focus, direction or area of research from those in which they are currently funded. In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

The qualifications for a candidate for the Brian D. Novis Senior Research Award include the following:
· Ability to provide a completed application with evidence of a meritorious research project.
· Must complete and return application package to the IMF no later than Tuesday, September 2nd.

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
USA
phone: 800-452-2873 (US and Canada)
818-487-7455 (elsewhere)
fax: 818-487-7454
email: TheIMF@myeloma.org

INTERNATIONAL MYELOMA FOUNDATION
2009 Brian D. Novis Research Award
Junior Grant
Provided by donations from private individuals

Deadline: on or before September 2nd, 2008.

The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma. This year's awards will be in the amount of $50,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward prevention and a cure.

QUALIFICATIONS
The qualifications for a candidate for the Brian D. Novis Research Award include the following:
· Completed postdoctoral studies or clinical fellowships not later than August 1 of the application year.
· Ability to devote a minimum of 50% of his or her time to the research project during the Award year.
· Ability to provide a completed application with evidence of a meritorious research project.
· Must complete and return application package to the IMF no later than September 2, 2008.

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
USA
phone: 800-452-2873 (US and Canada)
818-487-7455 (elsewhere)
fax: 818-487-7454
email: TheIMF@myeloma.org

The Bone Marrow Foundation Patient Aid Program
FILLING IN THE GAPS

Transplant patients and their families face enough challenges without added worries over money. Yet health insurance only covers part of a transplant’s total cost. The Bone Marrow Foundation’s Patient Aid Program lessens the burden of transplant-related expenses, offering direct financial assistance for donor searches, compatibility testing, bone marrow or stem cell collection, cord blood banking, medications, medical equipment, home and child care services, housing expenses, and transportation. It’s the only program that doesn’t limit patient assistance to specific diagnosis or age range, and that has relationships with bone marrow transplant centers across the country.

The application for the Patient Aid Program requires information about diagnosis, treatment, financial status and information from your social worker and physician. If you are interested in applying for a Patient Aid Program grant, please contact your physician, nurse coordinator or social worker for a Patient Aid Application. If you would like further information, please contact us at 1-800-365-1336 or email us at TheBMF@BoneMarrow.org.

Institute for Neuroacanthocytosis Research Grants

We encourage applications for research grants for investigations into the genetics, diagnostics and epidemiology of the NA syndromes as well as the pathophysiology and the related red blood cell abnormalities.
Neuroacanthocytosis syndromes are a group of rare diseases, characterised by misshaped erythrocytes and progressive neurodegeneration, causing movement disorders and neuropsychiatric symptoms.

The rarity and wide geographical spread of the NA diseases have contributed to a number of different researchers principally in Europe and Japan pursuing specific studies of the elements of the NA phenotypes including descriptive history of the development of the disease, the abnormalities of the erthrocytes and the function of the VPS 13A protein that is absent in chorea-acanthocytosis.

Since acanthocytosis is part of the NA syndromes clinical manifestations, the study of acanthocytes may offer the possibility to progress in the disease’ knowledge, to identify new cell signalling pathways towards either membrane proteins or transport systems.

Our Objectives for Research

To pursue the fundamental physiological questions raised by NA including the:

role of the proteins affected by the mutated genes in each disease as well as their molecular and cellular function

cause and significance of the spiky red blood cell membranes that are a defining characteristic of the diseases

pathway that leads to neuronal apoptosis in each of the diseases

To promote wide collaboration in the clinical study of the diseases. Because no country has more than an estimated 100 cases of NA and most countries in the world have fewer than 10 cases, it is vital that case histories of patients from around the world be available to those studying the clinical aspects of the diseases.

To develop the tools and the skill of neurologists to diagnose and, in the future, to treat the diseases.

To collaborate effectively with research into other similar conditions especially Huntington’s disease.

To encourage new, promising projects with seed money and assist in approaching larger grantors.

Our Values

Our funding seeks to:

Promote basic, curiosity-driven, investigator–led research that relates to the phenotypes of the NA diseases.

Bring together the wide research community around the world including haematology, cell biology, neuroscience and neuropsychiatry.

Encourage the wide dissemination of and free access to the research we support. We will seek to support unrestricted access and the public benefit wherever possible by requiring electronic copies of any research papers that have been accepted for publication in a peer-reviewed journal and are supported by the Advocacy to be deposited into PubMed Central (PMC) to be made freely available as soon as possible and in any event within six months of the journal publisher’s official date of final publication.

Do every thing possible to have strong communication with researchers receiving grants to assure that funds are used for the intended purpose.

Promote good communications between those working on NA research and others concerned with other diseases of the basal ganglia.

 

HISTIOCYTOSIS ASSOCIATION OF AMERICA
2008 GRANT APPLICATION
The Histiocytosis Association of America is a nonprofit organization dedicated to
assisting those affected by any of the several histiocytic syndromes, to encouraging
and supporting research on the causes and treatment of these disorders, and to
providing support and information to patients and families. Proposals are being
accepted for research into the causes and mechanisms of these disorders and
improved means of treatment.
Grants up to $50,000 USD each, will be awarded.
APPLICATIONS MUST BE RECEIVED BY
AUGUST 1, 2008
GRANTS TO BE AWARDED
NOVEMBER 2008
Applications accepted by email only
grants@histio.org
Histiocytosis Association of America
332 North Broadway • Pitman, New Jersey 08071 USA
Phone: +1 856 589 6606 • Website: www.histio.org
Histiocytosis Association of America Grant Application Page 2 of 4
HAA GRANT PROGRAM AREAS OF INTEREST
Proposals will be evaluated on the basis of science, feasibility and relevance. Listed below
are some areas of interest; however, all relevant proposals are encouraged and will be
considered.
• Cytogenetic abnormalities in LCH and other histiocytic disorders
• Studies of genetic defects underlying HLH
• Studies of surface antigen profile of LCH lesional cells
• Cytokine production in histiocytic syndromes
• Mechanism of dendritic cell homing
• Humoral and cellular immune responses in histiocytic disorders
• CNS pathology in histiocytic syndromes
• Marker studies for hemophagocytic syndromes
• Focused studies on Erdheim-Chester disease, Juvenile xanthogranuloma
• Sinus histiocytosis with massive lymphadenopathy
• Langerhans cell histiocytosis in adults
• Mechanisms of disease pathogenesis in LCH and HLH
• Immune function studies in the histiocytoses

HAA GRANT APPLICATION INFORMATION
REQUIREMENTS FOR SUBMISSION OF APPLICATION
• Applications must be emailed, as a single file attachment, to the Association at grants@histio.org
no later than August 1, 2008. It is preferable that the file be a Microsoft Word document. You will
receive an acknowledgement by return email confirming receipt of your application.
• The successful grant recipient is required to provide a written six-month status report to the HAA.
At the completion of the 1-year grant period, a written conclusion must be provided. The format of
the report will be sent to investigators prior to report due dates.
• Section C of the application may not exceed 10 pages; applications exceeding this specified
limit of 10 pages will be returned without review.
• Applicants must indicate other sources of funding.
GENERAL INFORMATION REGARDING THE GRANT PROGRAM
• Grants are awarded for one (1) year projects up to the amount announced. Applications in excess
of the announced amount or for periods longer than one (1) year will not be reviewed.
• Proposals will be reviewed and scored by the Histiocyte Society Scientific Committee for relevance,
science and feasibility. After the Histiocytosis Association of America (HAA) receives the collated
score from this review, the proposals will then be distributed to the scientific members of the HAA
Board of Trustees to be placed in priority order for available funding.
• Applications may receive an unaffiliated, outside review.
• The HAA does not fund overhead costs or travel budgets.
• A site visit may occur prior to the awarding of any grant.
• At the completion of the grant and upon review of the results, if the investigator can substantiate the
need for and value of further scientific inquiry into the results of the project, then he/she is
encouraged to submit an application for further funding, upon announcement of availability of
Association grant funds.
• Applications by new investigators are strongly encouraged.
• All results and findings are to be public and any published material or presentations are to
acknowledge the support of the Histiocytosis Association of America.
• Investigators are strongly encouraged to present their findings at the Annual Meeting of the
Histiocyte Society following completion of the project.

Guidelines for Applying for an Unrestricted Grant

The CSL Behring Foundation for Research and Advancement of Patient Health offers a type of grant designed to assist small, community-based organizations in delivering their many valuable services to the communities they serve.

The CSL Behring Foundation intends to award up to five $10,000 unrestricted grants per year (applications will only be accepted during the second grant cycle each year). Grants in this category will be evaluated on their merits, non-competitively with other applicants.

To apply and qualify, patient organizations MUST meet the following criteria:

* Be a recognized patient organization for persons with bleeding disorders
* Have an annual operating budget of less than $100,000
* Provide payment for staff services to two or less people
* Have obtained 501(c)(3) tax status
* Have not received unrestricted grant support from the CSL Behring Foundation previously

How to Apply

To apply for an unrestricted grant, please use the unrestricted grant application form.

To apply, submit a brief statement of how the funds would be used. The proposed use of the funds could be as simple as helping to fund ongoing operations, securing or upgrading office equipment, or seed money for starting a new program.

If more than five applications are received and deemed eligible, lots would be drawn to select winners.

In order to apply for this grant, please apply using the unrestricted grant application and email to CB.Foundation@cslbehring.com. Unrestricted grant requests are reviewed annually only. Proposals for unrestricted grants must be received by the CSL Behring Foundation no later than July 31st, 2008. Unrestricted grant awards will be announced in October 2008.

To receive a grant application, call the CSL Behring Foundation toll free at 1-866-963-2566

For guidance and suggestions on writing a compelling grant proposal, please visit the CSL Behring Foundation website at www.cslbehringfoundation.com and review the “Grant Writing Guidelines” section.